Executive appointment at Xenon
This article was originally published in Scrip
Executive Summary
Xenon Pharmaceuticals has appointed Dr Tarek Mansour as its executive vice-president of research and development. Dr Mansour recently served as vice-president, chemical sciences head over multiple research sites at Wyeth (now Pfizer) and has spent over 25 years in the industry. Xenon is a privately owned clinical genetics-based drug discovery company based in Vancouver, Canada, that has two pain medicine candidates in early-stage clinical development.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.